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A fully integrated microfluidic device for point-of-care monitoring 
of antithrombotics 
L. F. Harris,a P. Raineyb,  T. L. Lindahlc, and A. J. Killardd,† 
The simplicity and efficiency of point of care diagnostics have revolutionised patient care. Current methods for measuring 
hypercoagulability often require trained technicians, large blood volumes, and result in long turnaround times. Standard 
testing for hypercoagulable disorders is performed in the central laboratory using automated coagulation analysers. 
However the trend is moving towards the development and implementation of point of care testing, as a result of the ever 
increasing number of patients on antithrombotic therapy. We present a novel microfluidic device and assay for monitoring 
the effect of two anticoagulants, unfractionated heparin (UFH) and low molecular weight heparin (LMWH). The assay is 
based on the anti-Xa assay principle but uses fluorescence detection. Our device is a disposable laminate microfluidic strip, 
fabricated from the cyclic polyolefin (COP), Zeonor®, which is extremely suitable for application to fluorescent device 
platforms. We present data on the execution of the anti-Xa assay in this microfluidic format, demonstrating that the assay 
can be used to measure both UFH and LMWH in human plasma samples from 0 to 1 U/mL, with a rapid result obtained 
within 30-60 seconds.  
Introduction 
Antithrombotics are commonly administered for the treatment of 
arterial and venous thromboembolism. Unfractionated heparins 
and low molecular weight heparins are some of the traditional 
antithrombotics used in the treatment and prevention of such 
thromboembolic disorders.1 Low molecular weight heparin (LMWH) 
has a more defined and predictable pharmacokinetic or 
pharmacodynamic profile over unfractionated heparin (UFH) and it 
also prefers FXa as a therapeutic target over thrombin.2 
Standard testing for coagulation disorders are usually based on the 
principle of clotting and are carried out on automated 
coagulometers.3 However with the advent of point of care (POC) 
diagnostics, many of the standard clotting assays such as the 
prothrombin time (PT) and activated partial thromboplastin time 
(aPTT) have been translated into miniaturised POC devices. 
Warfarin is commonly monitored using the HemoSense INRatio 
monitor (HemoSense Inc., USA) which was developed for 
determining the PT/INR of patients undergoing oral anticoagulation 
treatment. Testing for anticoagulant therapy is very diverse with 
numerous different tests available for assessing coagulation status, 
however diagnostics based on the traditional testing principles are 
limited in terms of poor predictive value, poor quality and 
accuracy.4 As a result there is a drive for the standardization of 
current coagulation tests alongside a constant push for the 
development of a global test of haemostasis.5 
The emergence of peptide substrates in the 1960s6, had a knock-on 
effect with the development of substrates specific for coagulation 
proteins. As a result, the chromogenic anti-factor Xa (anti-FXa) 
assay emerged as the new standard for monitoring LMWH therapy 
in the central laboratory. The anti-FXa assay works on the principle 
of the addition of exogenous FXa to a heparinised plasma sample, 
which is incubated to allow the antithrombin (AT) in the sample to 
form a complex with the excess FXa and heparin. The formation of 
this complex allows AT to bind and inihibit thrombin and FXa more 
strongly. The concentration of free FXa can then be measured using 
a substrate that is selectively cleaved by the serine protease activity 
of FXa.7 Once cleaved, the peptide substrate will release a 
chromophore that can be detected colorimetrically. 
As the field of microfluidics has advanced, POC technologies have 
also developed and improved. Methods in microfabrication and 
microfluidics have progressed so much in the last few years that 
POC devices can be fabricated  at low cost, they are easy to use, 
portable and can generate rapid results.8,9 Silicon, glass, and 
polymers are often the substrates of choice in the manufacture of 
microfluidic devices as their chemical and physical properties are 
well characterized. Silicon and glass can pose issues due to costly 
fabrication processes, while polymers are low cost. Polymer-based 
materials are highly versatile in that they suit many modes of 
fabrication, are suitable for modification with surface chemistries 
and are also highly reproducible.10 In the current study we have 
used cyclic polyolefins (COPs) which belong to a class of polymers 
employed due to their compatibility with biological materials, low 
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autofluorescence, long shelf life and suitability for surface 
modification amongst others.11,12 Multilayer alignment fabrication 
methodologies are commonly used to develop functional 
microdevices13,14, as lamination of polymer layers offers greater 
versatility and low cost. Zeonor® was chosen for this study, in 
conjunction with PSA (pressure sensitive adhesive), as both are 
suitable materials for simple fabrication and lamination 
methodologies.15  
In our study we have developed a low cost, disposable, miniaturised 
POC device. We have developed a three layered hybrid chip, 
comprised of native hydrophobic Zeonor®, treated hydrophilic 
Zeonor® and a PSA spacer that forms the channel.16 The assay is 
incorporated onto the chip and works on the basis of the anti-Xa 
principle outlined above. Using fluorescence as the method of 
detection, the assay is capable of measuring therapeutic 
concentrations of heparin in calibration plasmas from 0-1 U/mL and 
in plasma samples from patients on heparin therapy. 
Experimental 
Reagents 
Water (ACS reagent) and HEPES (minimum 99.5% titration) were 
purchased from Sigma-Aldrich (Dublin, Ireland). Filtered HEPES was 
prepared at a concentration of 0.01 mM (pH 7.4). A 100 mM filtered 
stock solution of CaCl2 from Fluka BioChemika (Buchs, Switzerland) 
was prepared from a 1 M CaCl2 solution. 
The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-
arginine-7-amino-4-methylcoumarin acetate (Pefafluor™ FXa) was 
purchased from Pentapharm (Basel, Switzerland). It was 
reconstituted in 1 ml of water having a stock concentration of 10 
mM, aliquoted, covered with aluminum foil to protect from 
exposure to light, and stored at -20 °C. Purified human FXa (serine 
endopeptidase; code number: EC 3.4.21.6) was obtained from 
HYPHEN BioMed (Neuville-Sur-Oise, France) and was reconstituted 
in 500 µl of PCR grade water to give a stock concentration of 4400 
nM. Unfractionated heparin (UFH) (sodium salt of heparin derived 
from bovine intestinal mucosa, H0777) was sourced from Sigma-
Aldrich (Dublin, Ireland). Low molecular weight heparin tinzaparin 
(Innohep®) was obtained from Leo Pharma (Ballerup, Denmark). 
Human pooled plasma was purchased from Helena Biosciences 
Europe (Tyne and Wear, UK). Lyophilized plasma was reconstituted 
in 1 ml of water and left to stabilise for at least 20 min at room 
temperature prior to use. 
Rolls of 188 µm thick cyclic polyolefin polymer (Zeonor®) were 
purchased from IBIDI GmbH (Munich, Germany). ARcare® 92712 50 
µm double sided pressure sensitive adhesive (PSA) and HY10-
coated Zeonor® was purchased from Adhesives Research (Limerick, 
Ireland). Sheets of 188 µm Zeonor® was treated with a hydrophilic 
coating from Hydromer Inc. (NJ, USA). Conjugate pads (CP) Type 
8301 p/n SMCONO1 were sourced from Pall Europe Ltd. 
(Portsmouth, England). Strip materials were cut using a Graphtec 
Vinyl Cutter, Model CE5000-40-CRP from Graphtec GB Limited 
(Wrexham, UK). Contact angle measurements were carried out 
using an FTA 200 analyser from First Ten Angstroms, Inc. (Virginia, 
USA). 
All fluorescent measurements were carried out at 37°C using an 
Olympus IX81 motorised fluorescent microscope sourced from 
Olympus Europa GmbH (Hamburg, Germany) housed within an 
incubation chamber with an attached Hamamatsu Orca ER digital 
camera, Model C4742-80-12AG from Hamamatsu Photonics 
(Hertfordshire, UK). Fluorescence was monitored according to the 
following settings: magnification ×10; excitation at 342 nm and 
emission at 440 nm; exposure time of 20 ms. All values of 
fluorescence are reported as arbitrary fluorescence units (AU). All 
measurements were analyzed using the CellˆR realtime imaging 
software from Mason Technology (Dublin, Ireland) with subsequent 
data exportation into Excel, SigmaPlot 8.0, and SPSS 22.0 for 
analysis. 
 
Microfluidic Assay and Device Development 
Development of the microfluidic chip was divided into two stages. 
In the first stage the fluorogenic substrate was deposited within the 
microfluidic channel, while the FXa reagent was incubated 
externally with plasma prior to its application on-chip. The results of 
this study have been published previously.16 In the second stage of 
development, the aim was to develop a fully integrated device with 
all reagents incorporated on chip. 
 
Integrated Strip Development 
For the development of the integrated strip (Fig. 1), Zeonor® and 
PSA were cut into multichannel sheets (13 strips) using the 
Graphtec Vinyl Cutter (Fig. 2) from drawings designed using 
AutoCAD® 2007. The Zeonor® lid was cut with thirteen elliptical 
sample inlets of 4 mm diameter and rectangular outlets of 4 x 1.5 
mm to allow air to escape from inside the channels. The PSA 
channels were 50 mm long x 2 mm wide, with an additional area cut 
across the channels at the inlet end, which measured 15 mm in 
length by 5 mm width (Fig. 2). All 3 layers contain alignment marks 
for easy assembly. 
The CP was also cut to the same dimensions of 15 cm in length and 
5 mm wide (Fig. 2). Each CP was dip coated in 200 µl of FXa and left 
to dry for 2 hours in a desiccator at 19°C and 10% RH. Dip coating of 
the conjugate pad took place in a “microdip tank vessel”. A scalpel 
was used to cut the bulb and nozzle from a disposable pipette. The 
trough created from the bulb is used to contain the FXa. The pipette 
tip is placed over the needle, to provide a roller which attempts to 
mimic a standard dip tank coating procedure, while avoiding metal 
contamination from the needle. Both parts are disposed of after 
use to avoid cross contamination with future batches. 
The PSA layer was bonded to the Zeonor® lid layer using the 
alignment marks and 2 µl of Pefafluor™ FXa fluorogenic substrate 
was deposited with a pipette within each channel as four 0.5 µl 
droplets onto the hydrophobic Zeonor® at a distance of 1.5 mm 
from the outlet. Sheets were dried for 2 hours in a glass desiccator 
with silica at 19°C and 10% RH. After drying, the CP was inserted 
into the cut rectangular area on the PSA and bonded to the 
hydrophilic Zeonor® base layer using pressure lamination.  
Once the strip was assembled, 20 µl of re-calcified plasma (44 µl 
heparinized plasma + 6 µl 100 mM CaCl2) was immediately applied 
to the inlet of the assay strip. Plasma samples were spiked with 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
pharmacologically relevant concentrations (0–1 U/mL) of UFH and 
LMWH. 
 
 
Fig. 1. Schematic of the microfluidic chip highlighting the 
hydrophobic Zeonor® lid layer (with inlet and outlet), the PSA 
microchannel layer and the hydrophilic Zeonor base layer with 
deposited reagents. The image to the right incorporates the 
microdevice with a miniaturised detection system. 
 
 
Fig. 2. Multichannel Zeonor® lid layer (A), PSA channel layer (B) and 
CP containing the FXa reagent (C). The PSA layer containing the CP 
in the inlet area, was sandwiched between the hydrophilic Zeonor® 
lid layer and a hydrophobic Zeonor® base layer. 
 
 
Patient Samples 
A small preliminary study using patient samples was carried out. 
Plasma samples from patients on UFH were kindly donated by 
Tomas Lindahl based in the Linköping University Hospital, Sweden. 
Ten plasma samples from patients on UFH were collected and 
tested on our microfluidic device platform. Correlations were 
performed with the assay standard, aPTT for UFH. Patient samples 
were thawed at 37 °C in a water bath for 5 min and inverted for 5 
min before testing on the anti-FXa microfluidic device. All 
measurements were carried out in triplicate. 
Results and Discussion 
Strip materials characterisation and selection 
Zeonor® was selected as the polymer of choice for microfluidic chip 
development due to excellent optical characteristics for 
fluorescence measurements. A range of surface modifications were 
tested to render the hydrophobic Zeonor® surface hydrophilic. This 
allowed for capillary fill of the microfluidic chip. A range of 
materials were tested in terms of autofluorescence, capillary fill, 
and contact angle (Table 1). 
 
Table 1: Comparison of commercial hydrophilic surfaces in terms of 
fluorescence, capillary fill, contact angle and the variability 
associated with each measurement parameter (n=3). 
 
 
 
The HY10 treatment was not selected owing to its significant 
contribution to background fluorescence (640.9 AU ± 2.3). 
Fluorescence readings from the IBIDI Zeonor® and the Hydromer 
Zeonor® were comparable, but the wettability of the IBIDI 
treatment was poor by comparison with contact angles of 63.4º ± 
2.8. As a result the Hydromer treated Zeonor® was selected with a 
low autofluorescence (208.5 AU) in the UV spectrum, low contact 
angles (17.5º ± 0.9) and capillary fill times of 20.3s ± 2.1. 
A hybrid microfluidic device was developed by combining 
unmodified Zeonor® with Hydromer-coated Zeonor®. This allowed 
for deposition of reagent onto the hydrophobic film, while the 
hydrophilic film served to induce capillary fill. The final assay 
configuration was a three layer laminate chip comprising a 188 µm 
thick hydrophilic base, a 50 µm PSA spacer with a channel, into 
which the conjugate pad was inserted and a 188 µm thick 
hydrophobic Zeonor® lid. 
Assay Optimisation and Development 
 
For the microfluidic chip developed, FXa and Pefafluor FXa™ 
fluorogenic substrate were titrated within the range of 560-760 nM 
and 100-400 µM respectively. Fig. 3 (a) shows the typical 
fluorescence profiles of a fixed concentration of 600nM FXa to 
varying concentrations of Pefafluor™ FXa substrate and Fig. 3 (b) 
shows the fluorescence responses at 60 s for 560-700 nM FXa and a 
fixed concentration of 300 µM Pefafluor™ FXa in plasma at 
concentrations of 0, 0.5 and 1 U/mL UFH. The optimal fluorogenic 
substrate concentration was selected at a concentration that did 
not limit the conversion of the substrate to product, which was 
660nM returning an R2 of 0.98. 
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Fig. 3. (a) Typical profiles of the anti-Xa assay at a fixed 
concentration of 660 nM FXa and varying concentrations of 
Pefafluor™ FXa. (b) Fluorescence responses at 30 s for a range of 
FXa concentrations and a fixed concentration of 300 µM Pefafluor™ 
FXa at 0, 0.5, and 1 U/mL UFH (n=3).  
 
 
To select the optimal FXa concentration, the effect of heparin was 
analyzed using regression analysis (Fig. 4). The optimal 
concentration of FXa was selected that resulted in a wider signal 
range than other concentrations, small error and an R2 value close 
to 0.99. The optimal concentrations were selected as 300 µM 
Pefafluor™ FXa substrate and 660 nM FXa for the final assay 
development of the UFH assay (Fig. 4a). The FXa and Pefafluor™ FXa 
fluorogenic substrate concentrations for the LMWH assay were 
optimized as previously using regression analysis (Fig. 4b). Final 
concentrations were selected as 650 nM FXa and 600 µM 
Pefafluor™ FXa fluorogenic substrate. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Linear regression analysis of fluorescent responses at 30, 60 
and 90 seconds for (a) UFH and (b) LMWH. The fluorescence value 
@ 30 seconds was selected as the most appropriate parameter for 
measuring UFH, while the fluorescence value at 60 seconds was the 
most appropriate measurement parameter for LMWH. 
 
 
The fluorescence responses of the optimized assay conditions were 
tested over a range of UFH and LMWH concentration. The 
concentration of heparin is inversely proportional to the rate of 
fluorescence formation. As the concentration of drug increases, the 
rate of fluorescence product formation decreases. Fig. 5 outlines 
the dose response curves of human plasma spiked with UFH and 
LMWH in the anti-Xa device. Various methods were investigated for 
optimal data analysis and extraction, but the fluorescence value at 
30 sec was most appropriate for UFH returning an R2 value of 0.98 
(y = -4309.3x + 4061.1) (Pearson = 0.99). The fluorescence value at 
60 sec was selected as the most appropriate value for LMWH giving 
an R2 value of 0.97 (y = -3630x + 4053.8) (Pearson = 0.99). Assay 
reproducibility was good with average CVs of <12% with one 
exception at 0.25 U/mL for both the UFH and LMWH assays. 
Variability at 0.25 U/mL was 35% for UFH and 19% for LMWH assay.  
Statistical analysis returned significant differences in the variances 
with the Levene’s test for the UFH assay (p = 0.007) and the LMWH 
assay (p = 0.009), so one-way ANOVA could not be applied. When 
equal variances were not assumed, the Tamhane test returned 
significant differences, however UFH at a concentration of 0.25 
U/mL resulted in significant error as a result of one outlier causing 
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insignificant differences between 0.25 U/mL and all other 
concentrations of UFH. The UFH assay had a statistically significant  
 
Fig. 5. Dose response curve of human plasma spiked with UFH from 
0 – 1 U/mL (R2 = 0.97) and LMWH from 0-1 U/mL (R2 = 0.99) in the 
anti-Xa device (n=3). 
 
 
range from 0 – 0.75 U/mL. The same pattern was also observed 
with the LMWH assay where 0.25 U/mL did not appear significantly 
different from 0 and 0.5 U/mL LMWH and 0.5 U/mL was not 
significantly different from 0.75 U/mL. This again could be 
attributed to the significant outlier encountered at 0.25 U/mL which 
resulted in a CV of 19%. Variability of 12% was also observed at 0.75 
U/mL. The LMWH assay had a statistically significant range from 0 – 
1 U/mL. 
 
Patient Analysis 
To evaluate the integrated device, 10 plasma samples from patients 
on UFH therapy were tested in the device. For these patients on 
UFH therapy, the fluorescence responses from all patients were 
converted into U/mL and correlated with the corresponding aPTT 
value from the hospital laboratory. The correlation can be seen in 
Fig. 6. 
 
 
 
Fig. 6: UFH correlation: Anti-Xa device and hospital aPTT assay. 
The fluorescence intensity value at 30 seconds was calculated for all 
UFH patient samples. From the data presented in Fig. 6 it can be 
seen that UFH generates a good correlation with a Pearson 
coefficient of 0.88. The trend observed is that with increasing 
fluorescence, the aPTT value decreases which is reflective of 
decreasing heparin concentrations. 
Quite a share of the POC market is occupied by coagulation 
monitoring devices. Many of these POC diagnostics are based on 
traditional methods and testing principles, such as clotting time 
determined by PT, aPTT or ACT (activated clotting time). The 
adaptation of many of these assays to POC devices was instigated 
by the significant need for more rapid analysis of coagulation status 
in emergency room settings.16 While these devices are commonly 
used and there is a demand for them, there is certainly scope for 
the development of novel devices that could improve upon 
conventional testing methods. 
The first move away from standard clot-based testing began in the 
1960s with the development and introduction of peptide substrates 
specific for coagulation proteins such as thrombin and plasmin.17,18 
Factor Xa was then identified as a significant protein in the 
coagulation cascade, occupying a pivotal position that could be 
targeted when monitoring anticoagulant therapy.19 The 
development of a FXa specific peptide substrate resulted in the 
emergence of the anti-Xa colorimetric assay in 1976 which was used 
to monitor heparin therapy.6 Central diagnostic laboratories refer to 
the the anti-Xa assay as the ‘gold standard’ assay for measuring 
heparin anticoagulant therapy. Despite its popularity, it has not yet 
been translated into a POC device. 
The work presented here focuses on the development of a POC 
device for monitoring anticoagulant therapy in cardiac patients that 
operates on the anti-Xa assay principle. Our initial aim was to 
develop a simple disposable chip that incorporates the anti-Xa 
assay. The simplicity of the chip is achieved through the mechanism 
of capillary fill, so there is no integration of complex, sophisticated, 
and costly instrumentation such as pumps or valves into the device. 
The chip was fabricated from 188 µm Zeonor® which is easily 
manipulated during manufacture on the Graphtec Vinyl Cutter. 
Other microfluidic techniques such as laser ablation or hot 
embossing can be costly to operate and often require skilled 
operators, compared to cutting plotters which are user friendly and 
low cost alternatives. 
As aforementioned, COP was chosen as the substrate material for 
this chip design as it offers additional advantages over polymers 
such as polycarbonate (PC) and polyethylene terephthalate (PET) in 
terms of its excellent optical clarity, high UV transmission, easy 
modification of its surface and suitability for disposable POC 
devices.20–22  
The concept of capillary force has long been used in lateral flow 
tests which are the most commercially successful POC platforms 
due to their simplicity.23 Native Zeonor® is highly hydrophobic 
which is suitable for reagent deposition but it becomes problematic 
when working with devices using capillary fill as it prevents flow. To 
render the Zeonor® surface hydrophilic, three surface chemistries 
were analyzed to modify the polymer. From the results obtained, 
the Hydromer-modified Zeonor® with low water contact angles of 
17.5° ± 0.9, produced the most reproducible capillary fill times of 
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20.3 s ± 2.1. The device was based on a joint 
hydrophilic/hydrophobic design to incorporate both the reagent 
deposition and capillary fill components of the device. The method 
of detection for this device is based on fluorescence, so Zeonor® 
was selected, as it resulted in low background fluorescence at 
wavelengths of 342 nm. Treatment with the HY10 coating resulted 
in responses of 640.9 ± 2.3 AU, which were too high in terms of 
background fluorescence. 
The fully integrated device developed showed sensitivity in the 
therapeutic ranges for UFH (0 – 0.75 U/mL) and LMWH (0 – 1 
U/mL). Average CVs were <11%, despite high CVs at 0.25U/mL 
which would be reduced with further device development. 
Comparisons on levels of sensitivity and precision can only be 
drawn with clot-based devices for heparin measurement currently 
on the market, as an optical POC system for anticoagulant 
monitoring is not currently available. Comparisons can be drawn 
with the Hemochron® systems which are some of the most 
commonly used POC coagulation devices on the market. 
Hemochron® aPTT measurements report linearity with heparin up 
to 1.5 U/mL, at intervals of 0.25 U/mL and CVs of <14%. Our system 
is also outperforming other POC diagnostics in terms of volume and 
turnaround times. The anti-Xa assay and device requires a small 
sample volume of 20 µl and results processed within 30 or 60 
seconds. This correlates with devices such as the CoaguCheck 
(Roche Diagnostics, UK), yet significantly lower than the 50 µl 
sample volume required for the Hemochron® systems. 
 
Conclusion 
In terms of patient analysis, plasma samples from patients on UFH 
were tested on the device and a Pearson correlation of 0.88 was 
achieved by comparing fluorescence with clotting time. With low 
heparin concentrations, fluorescence intensities are high and 
clotting times are short. Here we present preliminary results of a 
POC anti-Xa device but with further development, the fluorogenic 
anti-Xa assay and device could prove successful for near-patient 
monitoring of antithrombotics with the knock-on effect of 
improving the health of patients on anticoagulant drugs. 
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